Related references
Note: Only part of the references are listed.Oxidative Stress Signaling Mediated Pathogenesis of Diabetic Cardiomyopathy
Zhaobing Tang et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2022)
Protective role of hydrogen sulfide against diabetic cardiomyopathy via alleviating necroptosis
Weiwei Gong et al.
FREE RADICAL BIOLOGY AND MEDICINE (2022)
The EMPEROR-Preserved study: end of the search for the Phoenix or beginning of a new season for trials in heart failure with preserved ejection fraction
Massimo Volpe et al.
EUROPEAN HEART JOURNAL (2021)
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
Deepak L. Bhatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
Suetonia C. Palmer et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
Electron Microscopy Revealed Massive Lipid Droplets in Cardiomyocytes in a Patient with Cardiogenic Shock a Fulminant 1 Diabetes Mellitus
Ryosuke Sugawara et al.
INTERNATIONAL HEART JOURNAL (2021)
The Effects of SGLT2 Inhibitors on Lipid Metabolism
Zsolt Szekeres et al.
METABOLITES (2021)
Diabetic fibrosis
Izabela Tuleta et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2021)
Cardiac Late Sodium Channel Current Is a Molecular Target for the Sodium/Glucose Cotransporter 2 Inhibitor Empagliflozin
Koenraad Philippaert et al.
CIRCULATION (2021)
Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors: Renoprotective Mechanisms beyond Glycemic Control
Tomoaki Takata et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Mitophagy in Diabetic Cardiomyopathy: Roles and Mechanisms
Haoxiao Zheng et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Theresa A. McDonagh et al.
EUROPEAN HEART JOURNAL (2021)
The Mystery of Diabetic Cardiomyopathy: From Early Concepts and Underlying Mechanisms to Novel Therapeutic Possibilities
Petra Grubic Rotkvic et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
Stefan D. Anker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Cardiomyopathy in obesity, insulin resistance and diabetes
Michinari Nakamura et al.
JOURNAL OF PHYSIOLOGY-LONDON (2020)
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
Francesco Cosentino et al.
EUROPEAN HEART JOURNAL (2020)
Basic Mechanisms of Diabetic Heart Disease
Rebecca H. Ritchie et al.
CIRCULATION RESEARCH (2020)
Effect of Luseogliflozin on Heart Failure With Preserved Ejection Fraction in Patients With Diabetes Mellitus
Kentaro Ejiri et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2020)
Combination therapy with pemafibrate (K-877) and pitavastatin improves vascular endothelial dysfunction in dahl/salt-sensitive rats fed a high-salt and high-fat diet
Masatoki Yoshida et al.
CARDIOVASCULAR DIABETOLOGY (2020)
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Milton Packer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Mitophagy Is Essential for Maintaining Cardiac Function During High Fat Diet-Induced Diabetic Cardiomyopathy
Mingming Tong et al.
CIRCULATION RESEARCH (2019)
Diabetic cardiomyopathy: factual or factoid?
Thiago Quinaglia et al.
REVISTA DA ASSOCIACAO MEDICA BRASILEIRA (2019)
Diabetic Cardiomyopathy What Is It and Can It Be Fixed?
Wolfgang H. Dillmann
CIRCULATION RESEARCH (2019)
Inhibitory Effects of Tofogliflozin on Cardiac Hypertrophy in Dahl Salt-Sensitive and Salt-Resistant Rats Fed a High-Fat Diet
Tomonari Kimura et al.
INTERNATIONAL HEART JOURNAL (2019)
JCS 2017/JHFS 2017 Guideline on Diagnosis and Treatment of Acute and Chronic Heart Failure - Digest Version -
Hiroyuki Tsutsui et al.
CIRCULATION JOURNAL (2019)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
J. J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Heart Failure in Type 2 Diabetes Mellitus Impact of Glucose-Lowering Agents, Heart Failure Therapies, and Novel Therapeutic Strategies
Helena C. Kenny et al.
CIRCULATION RESEARCH (2019)
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk The CARMELINA Randomized Clinical Trial
Julio Rosenstock et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Ranolazine prevents pressure overload-induced cardiac hypertrophy and heart failure by restoring aberrant Na+ and Ca2+ handling
Jiali Nie et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Role of Pyroptosis in Cardiovascular Diseases and its Therapeutic Implications
Cheng Zeng et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2019)
Metabolic Slowing and Reduced Oxidative Damage with Sustained Caloric Restriction Support the Rate of Living and Oxidative Damage Theories of Aging
Leanne M. Redman et al.
CELL METABOLISM (2018)
Do DPP-4 Inhibitors Cause Heart Failure Events by Promoting Adrenergically Mediated Cardiotoxicity?: Clues From Laboratory Models and Clinical Trials
Milton Packer
CIRCULATION RESEARCH (2018)
Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity
Guanghong Jia et al.
CIRCULATION RESEARCH (2018)
A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity
Motoaki Sano
JOURNAL OF CARDIOLOGY (2018)
Cellular death, reactive oxygen species (ROS) and diabetic complications
Caroline Maria Oliveira Volpe et al.
CELL DEATH & DISEASE (2018)
Changes in heart rate in patients with type2 diabetes mellitus after treatment with luseogliflozin: Subanalysis of placebo-controlled, double-blind clinical trials
Motoaki Sano et al.
JOURNAL OF DIABETES INVESTIGATION (2018)
Empagliflozin Ammeliorates High Glucose Induced-Cardiac Dysfuntion in Human iPSC-Derived Cardiomyocytes
Kwong-Man Ng et al.
SCIENTIFIC REPORTS (2018)
Aldose Reductase Mediates NLRP3 Inflammasome-Initiated Innate Immune Response in Hyperglycemia-Induced Thp1 Monocytes and Male Mice
Pabitra B. Pal et al.
ENDOCRINOLOGY (2017)
Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2
Vance B. Matthews et al.
JOURNAL OF HYPERTENSION (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Cardiac oxidative stress in diabetes: Mechanisms and therapeutic potential
Alyssa Faria et al.
PHARMACOLOGY & THERAPEUTICS (2017)
Diabetic cardiomyopathy: where we are and where we are going
Wang-Soo Lee et al.
KOREAN JOURNAL OF INTERNAL MEDICINE (2017)
Effect of a selective SGLT2 inhibitor, luseogliflozin, on circadian rhythm of sympathetic nervous function and locomotor activities in metabolic syndrome rats
Asadur Rahman et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2017)
Postprandial hyperlipidemia as a potential residual risk factor
Kazufumi Nakamura et al.
JOURNAL OF CARDIOLOGY (2016)
Diabetes-associated cardiac fibrosis: Cellular effectors, molecular mechanisms and therapeutic opportunities
Ilaria Russo et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2016)
Late sodium current: A mechanism for angina, heart failure, and arrhythmia
Jonathan C. Makielski
TRENDS IN CARDIOVASCULAR MEDICINE (2016)
Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial
Hiroki Oe et al.
CARDIOVASCULAR DIABETOLOGY (2015)
Diabetic Cardiomyopathy Catabolism Driving Metabolism
Zhao V. Wang et al.
CIRCULATION (2015)
Comment on Nolan et al. Insulin Resistance as a Physiological Defense Against Metabolic Stress: Implications for the Management of Subsets of Type 2 Diabetes. Diabetes 2015;64:673–686
Heinrich Taegtmeyer et al.
DIABETES (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Jennifer B. Green et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Diabetes-Related Heart Failure - Does Diabetic Cardiomyopathy Exist?
Yasuko K. Bando et al.
CIRCULATION JOURNAL (2014)
Advanced glycation end products: role in pathology of diabetic cardiomyopathy
Vijaya Lakshmi Bodiga et al.
HEART FAILURE REVIEWS (2014)
NLRP3 Gene Silencing Ameliorates Diabetic Cardiomyopathy in a Type 2 Diabetes Rat Model
Beibei Luo et al.
PLOS ONE (2014)
Comparative Safety and Effectiveness of Metformin in Patients With Diabetes Mellitus and Heart Failure Systematic Review of Observational Studies Involving 34 000 Patients
Dean T. Eurich et al.
CIRCULATION-HEART FAILURE (2013)
2013 ACCF/AHA Guideline for the Management of Heart Failure A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
Clyde W. Yancy et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Association of Epicardial Fat With Cardiovascular Risk Factors and Incident Myocardial Infarction in the General Population
Amir A. Mahabadi et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
A Novel Paradigm for Heart Failure With Preserved Ejection Fraction Comorbidities Drive Myocardial Dysfunction and Remodeling Through Coronary Microvascular Endothelial Inflammation
Walter J. Paulus et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
William B. White et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Benjamin M. Scirica et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Low serum magnesium concentrations are associated with a high prevalence of premature ventricular complexes in obese adults with type 2 diabetes
Liana C. Del Gobbo et al.
CARDIOVASCULAR DIABETOLOGY (2012)
Ventricular Assist Device Implantation Corrects Myocardial Lipotoxicity, Reverses Insulin Resistance, and Normalizes Cardiac Metabolism in Patients With Advanced Heart Failure
Aalap Chokshi et al.
CIRCULATION (2012)
Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: Evidence from a 37,229 patient meta-analysis
Davide Castagno et al.
AMERICAN HEART JOURNAL (2011)
Lipotoxicity in type 2 diabetic cardiomyopathy
Tineke van de Weijer et al.
CARDIOVASCULAR RESEARCH (2011)
Repetitive hypoglycaemia increases serum adrenaline and induces monocyte adhesion to the endothelium in rat thoracic aorta
W. L. Jin et al.
DIABETOLOGIA (2011)
Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials
Remy Boussageon et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study
C. Andersson et al.
DIABETOLOGIA (2010)
Type 1 diabetic cardiomyopathy in the Akita (Ins2WT/C96Y) mouse model is characterized by lipotoxicity and diastolic dysfunction with preserved systolic function
Ratnadeep Basu et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2009)
Metformin Prevents Progression of Heart Failure in Dogs Role of AMP-Activated Protein Kinase
Hideyuki Sasaki et al.
CIRCULATION (2009)
Cardiac Adiposity and Global Cardiometabolic Risk - New Concept and Clinical Implication
Michio Shimabukuro
CIRCULATION JOURNAL (2009)
Activation of AMP-Activated Protein Kinase by Metformin Improves Left Ventricular Function and Survival in Heart Failure
Susheel Gundewar et al.
CIRCULATION RESEARCH (2009)
Diastolic transient inward current in long QT syndrome type 3 is caused by Ca2+ overload and inhibited by ranolazine
N. Lindegger et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2009)
Relationship of Hemoglobin A1C and Mortality in Heart Failure Patients With Diabetes
David Aguilar et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Proinflammatory cytokines in response to insulin-induced hypoglycemic stress in healthy subjects
Laleh Razavi Nematollahi et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2009)
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database
Ioanna Tzoulaki et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Ceramide is a cardiotoxin in lipotoxic cardiomyopathy
Tae-Sik Park et al.
JOURNAL OF LIPID RESEARCH (2008)
Dyslipidaemia in type II diabetic mice does not aggravate contractile impairment but increases ventricular stiffness
An Van den Bergh et al.
CARDIOVASCULAR RESEARCH (2008)
Classification of the cardiomyopathies: a position statement from the european society of cardiology working group on myocardial and pericardial diseases
Perry Elliott et al.
EUROPEAN HEART JOURNAL (2008)
Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials
Rodrigo M. Lago et al.
LANCET (2007)
Diabetic cardiomyopathy revisited
Sihem Boudina et al.
CIRCULATION (2007)
Mechanisms of disease: pathway-selective insulin resistance and microvascular complications of diabetes
PH Groop et al.
NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM (2005)
Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure
SD Katz et al.
CIRCULATION (2005)
Decreased sarcoplasmic reticulum activity and contractility in diabetic db/db mouse heart
DD Belke et al.
DIABETES (2004)
Burden of systolic and diastolic ventricular dysfunction in the community - Appreciating the scope of the heart failure epidemic
MM Redfield et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cell - The role of protein kinase C and NAD(P)H-oxidase activation
L Quagliaro et al.
DIABETES (2003)
Deactivation of peroxisome proliferator-activated receptor-α during cardiac hypertrophic growth
PM Barger et al.
JOURNAL OF CLINICAL INVESTIGATION (2000)
Share Paper
